Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Leases (2024 - 2025)

Axsome Therapeutics (AXSM) has disclosed Capital Leases for 2 consecutive years, with $4.2 million as the latest value for Q4 2025.

  • Quarterly Capital Leases rose 42.92% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2025, up 42.92% year-over-year, with the annual reading at $4.2 million for FY2025, 42.92% up from the prior year.
  • Capital Leases hit $4.2 million in Q4 2025 for Axsome Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $4.7 million in Q3 2025 to a low of $1.7 million in Q1 2024.